BOLT

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) is a clinical-stage biotechnology company founded in 2015 and headquartered in Redwood City, California. The company went public in February 2021 and focuses on developing innovative immuno-oncology therapies designed to harness the body's immune system to eliminate cancer cells. Originally incorporated as Bolt Therapeutics, Inc., the company changed its name to Bolt Biotherapeutics in July 2015 to better reflect its focus on biological therapeutics. The company has undergone significant strategic restructuring in recent years, including substantial workforce reductions and pipeline prioritization to extend its operational runway.